Primary Processor Scombrotoxin Controls - Overview and Testing at Receiving
This video presents FDA’s recommendations for primary processors to control the hazard of scombrotoxin (histamine) formation when receiving raw scombrotoxin-forming fish species. FDA recommends two primary processor control strategies; the Histamine Testing Control Strategy and the Harvest Vessel Record Control Strategy. This video focuses on HACCP control elements related to internal temperature measurements, sensory examinations, and, where applicable, histamine testing activities associated with both control strategies A separate video presents primary processor controls specific to the development and use of harvest vessel records as a primary processor HACCP control.

▶︎
FDA Fish and Fishery Products and Hazards Controls Guidance, 4th Edition: Introduction and Overview

▶︎
Employees are the FIRST Line of Food Defense (English)

▶︎
FDA Grand Rounds - Pharmacovigilance in Practice: From Safety Signals to Regulatory Action

▶︎
CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

▶︎
CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

▶︎
AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products

▶︎
Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing

▶︎
OTP Town Hall: Best Practices for Preparing BLA Submissions for Cell and Gene Therapy Products

▶︎
ClinicalTrials.gov: Essentials for Academic Medical Centers – Pre-recorded Training Video

▶︎
Conversations on Cancer: Patient first = Project Facilitate

▶︎
AGDD 2025 | D1S02 - Session 2: Q&A Discussion Panel

▶︎
Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims

▶︎
AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice

▶︎
FDA Direct: These 9 Drugs Were Awarded National Priority Vouchers

▶︎
AGDD 2025 | D1S01 - Product-Specific Guidance for Complex Products: From Research to Standards

▶︎
AGDD 2025 | D1S02 - Novel Bioequivalence Study Design Recommendations

▶︎
VRBPAC -- May 28 Meeting

▶︎
AGDD 2025 | D2S03-1 Session 3: Q&A Discussion Panel

▶︎
AGDD 2025 | D1S01 – Session 1: Q&A Discussion Panel

▶︎
